Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Rhea-AI Summary
Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 8:00 am ET in Miami, FL. The presentation will be available via webcast on the company's investor relations website, with replay access for at least 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – FULC
In the trading session that priced this news, FULC gained 2.46%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, FL on Wednesday, June 11, 2025 at 8:00 am ET.
The webcast of the fireside chat will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
